¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-04-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-04-26
±³À°ÀÏÀÚ : 2024-04-26
±³À°Àå¼Ò : º¤½ºÄÚ Á¦2Àü½ÃÀå

±³À°ÁÖÁ¦ : 2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÀÌÀº¿µ
¿¬¶ôó : 02-512-5915  

À̸ÞÀÏ : office@sgo.or.kr

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 350¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 13 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 150,000¿ø  

ºñ°í Àü¹®ÀÇ 15¸¸¿ø, ÀüÀÓÀÇ 13¸¸¿ø, Àü°øÀÇ 10¸¸¿ø, °£È£»ç/¿¬±¸¿ø 11¸¸¿øÇöÀåµî·Ï +4¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 08:30~08:50 AI-enhanced Pathology: Pathway to Precision in Oncology Á¶¼öÀÍ(·ç´Ö)

Åä·Ð 04¿ù 26ÀÏ 5AHall 08:50~09:00 Designated Discussion ¹Ú¼ºÅÃ(ÇѸ²ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 09:00~09:05 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 09:05~09:25 Locally advanced cervical cancer management Dimitrios Nasioudis (University of Pennsylvania, USA)

Åä·Ð 04¿ù 26ÀÏ 5AHall 09:25~09:35 Designated Discussion °øÅ¿í(¾ÆÁÖÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 09:35~09:40 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 09:50~10:00 (ÃʷϹßÇ¥) A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treatted with a PARP inhibitor (KGOG 3056/NIRVANA-R) Á¶Çö¿õ(°í·ÁÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 10:00~10:05 Distallate discussion À̼ºÁ¾(°¡Å縯ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 10:05~10:10 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 10:10~10:20 (ÃʷϹßÇ¥) Predicting microsatellite instability status in endometrial cancer using F-18 Fluorodeoxyglucose positron emission tomography/computed tomography radiomics ±èÁ¾¹Ì(°æºÏÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 10:20~10:25 Distallate discussion ÀÌ¿ëÀç(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 10:25~10:30 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 10:30~10:40 (ÃʷϹßÇ¥) Oncologic Outcomes and the Impact of Minimally Invasive Surgery in Early-Stage Cervical Cancer Patients Undergoing Radical Trachelectomy: A Korean Gynecologic Oncology Group Study (KGOG 1048) ±è´ë¿¬(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 10:40~10:45 Distallate discussion Dimitrios Nasioudis (University of Pennsylvania, USA)

Åä·Ð 04¿ù 26ÀÏ 5AHall 10:45~10:50 Floor discussion ()

ÈÞ½Ä 04¿ù 26ÀÏ 5AHall 10:50~11:10 Coffee break ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 11:10~11:20 (ÃʷϹßÇ¥) Development of a novel ex-vivo anticancer drug screening system for precision medicine in ovarian cancer patients ÀÌÁ¤¿ø(¼º±Õ°üÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 11:20~11:25 Distallate discussion ³ëÀçÈ«(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 11:25~11:30 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 11:30~11:40 (ÃʷϹßÇ¥) Analysis of improvement in overall survival rate when cervical cancer patients participate in clinical trials ±è¿ë¸¸(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 11:40~11:45 Distallate discussion Hiroaki Kobayashi(Kagoshima University, Japan)

Åä·Ð 04¿ù 26ÀÏ 5AHall 11:45~11:50 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 11:50~12:00 Emerging role of immuno-oncologics in cervical cancer Yang Xiang(Peking Union Medical College, China)

Åä·Ð 04¿ù 26ÀÏ 5AHall 12:00~12:05 Distallate discussion ½Å¼ÒÁø(°è¸íÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 12:05~12:10 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 12:10~12:25 Illuminating for EC Patients: Unveiling a New Treatment Paradigm in 1L EC Rebecca Kristeleit(HCA, UK)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 12:25~12:40 Enhancing HPV Management Through Risk Stratification: The Role of Dual Staining with p16 and Ki-67 ¹Î°æÁø(°í·ÁÀÇ´ë)

½Ä»ç 04¿ù 26ÀÏ 5AHall 13:10~13:30 Lunch ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 13:30~13:38 (ÃʷϹßÇ¥) Distinct Immune Characteristics and Differential Anti-PD-1-mediated Reinvigoration Potential of CD8+ TILs Based on BRCA1/2 Mutation Status in Epithelial Ovarian Cancer ¹ÚÁؽÄ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 13:38~13:46 (ÃʷϹßÇ¥) A comprehensive proteomics study to predict therapeutic responses to PARP inhibitors in high-grade serous ovarian cancer ±è¼¼ÀÍ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 13:46~13:54 (ÃʷϹßÇ¥) Time interval between completion of neoadjuvant chemotherapy and initiation of postoperative adjuvant chemotherapy affects the survival of patients with advanced ovarian cancer ¹éÁö¿ø(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 13:54~14:02 (ÃʷϹßÇ¥) Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis ÀÌ¿ëÀç(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 14:02~14:10 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 14:10~14:18 (ÃʷϹßÇ¥) Surgical outcomes of interval debulking surgery after neoadjuvant chemoimmunotherapy for advanced-stage ovarian cancer ÀÌÁøÇý(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 14:18~14:26 (ÃʷϹßÇ¥) Effect of Quality Control Program on Surgical Management in Advanced Ovarian Cancer ±èº¸¶ó(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 14:26~14:34 (ÃʷϹßÇ¥) FOXA1 FOXA1 gene that plays an important role in ovarian cancerthat plays an important role in ovarian cancer ¾çÀºÁ¤(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 14:34~14:42 (ÃʷϹßÇ¥) Hyperthermic Intraperitoneal Chemotherapy for Stage IV Epithelial Ovarian Cancer: A Critical Appraisal of Indications and Clinical Implications ¼ÕÁÖÇõ(¾ÆÁÖÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 5AHall 14:42~14:50 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 13:30~13:38 (ÃʷϹßÇ¥) Investigating L1CAM and ¥â-catenin as Prognostic Indicators in Fertility-Sparing Endometrial Cancer Treatment ¹ÚÁ¤¿­(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 13:38~13:46 (ÃʷϹßÇ¥) Hormone replacement therapy and risks of various cancers in postmenopausal women with de-novo or a history of endometriosis À̹æÇö(ÀÎÇÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 13:46~13:54 (ÃʷϹßÇ¥) Improving Preoperative Identification of Uterine Sarcomas: Analysis of Clinical and Imaging Characteristics À̽¹Ì(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 13:54~14:02 (ÃʷϹßÇ¥) Correlation between Mismatch Repair status and lymph node metastasis in endometrial cancer ¹Ú¹ÎÁ¤(ÀÎÁ¦ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 321/322/323/324 14:02~14:10 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 14:10~14:18 (ÃʷϹßÇ¥) Optimal Dietary Intake of Riboflavin Associated with Lower Risk of Cervical cancer in Korea : Korean National Health and Nutrition Examination Survey 2010-2021 À̼±¹Ì(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 14:18~14:26 (ÃʷϹßÇ¥) Impact of metformin on survival outcome in advanced cervical cancer: A Korean and Japanese Gynecologic Oncology Group (KGOG & JGOG) collaboration study ¹é¹ÎÇö(°­¿øÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 14:26~14:34 (ÃʷϹßÇ¥) A feasibility study of upcycled smartphone-based colposcopy for visual inspection of cervix performed by community healthcare workers in rural Vietnam ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 14:34~14:42 (ÃʷϹßÇ¥) A tissue factor bi-specific T cell engager provides effective targeting and cytotoxicity against cervical cancer cell lines Á¶Çý¿¬(ÇѸ²ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 321/322/323/324 14:42~14:50 Floor discussion ()

ÈÞ½Ä 04¿ù 26ÀÏ 321/322/323/324 14:50~15:20 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:20~15:28 (ÃʷϹßÇ¥) Assessing adverse Pregnancy outcomes and Fetal Malformations in Cancer Diagnosed During Pregnancy ¿À¿µÅÃ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:28~15:36 (ÃʷϹßÇ¥) Regularity of cervical cancer screening in Korea: analysis using national public data for 12 years ¹èÁÖ¿µ(°Ç¾çÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:36~15:44 (ÃʷϹßÇ¥) Lymphedema in Gynecological cancer survivor ; A Nationwide Cohort Study À̼öÁ¤(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:44~15:52 (ÃʷϹßÇ¥) Preliminary Study of Combination Treatment of Immune Checkpoint Inhibitors and Modulated Electro-hyperthermia in Recurrent Gynecologic Malignancies ¹®ÁöÇö(Â÷ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 321/322/323/324 15:52~16:00 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:20~15:30 (ÃʷϹßÇ¥) Pelvic ultrasound-based deep learning models for accurate diagnosis of ovarian cancer: retrospective multicenter study Á¶Çö¿õ(°í·ÁÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 321/322/323/324 15:30~15:33 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:33~15:43 (ÃʷϹßÇ¥) Prognostic implications of body composition in cervical cancer patients who underwent concurrent chemoradiation therapy as a primary treatment: a clinical research utilizing an artificial intelligence-based volumetrics ÀÓÇöÁö(Â÷ÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 321/322/323/324 15:43~15:46 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 15:46~15:56 Practical Use of ChatGPT and Generative AI on Clinical Research ÀÌÁ¤¹«(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 321/322/323/324 15:56~16:00 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 13:30~13:38 (ÃʷϹßÇ¥) COMPARISON OF SURVIVAL OUTCOMES BETWEEN SEQUENTIAL AND ¡®SANDWICH¡¯ SEQUENCING OF ADJUVANT CHEMO-RADIOTHERAPY IN ADVANCED STAGE ENDOMETRIAL CARCINOMA PATIENTS AT PHRAMONGKUTKLAO HOSPITAL AND NATIONAL CANCER INSTITUTE Ekasit Chaiamonsup(Phramongkutklao Hospital, Thailand)

Åä·Ð 04¿ù 26ÀÏ 121/122 13:38~13:40 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 13:40~13:48 (ÃʷϹßÇ¥) Toripalimab Combined With Bevacizumab And Chemotherapy As First-Line Treatment For Refractory, Recurrent Or Metastatic Cervical Cancer: A Single-Arm, Open-Label, Phase II Trial Chen Li(Peking Union Medical College, China)

Åä·Ð 04¿ù 26ÀÏ 121/122 13:48~13:50 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 13:50~13:58 (ÃʷϹßÇ¥) UBE2T-Mediated Stemness Enhancement: Unraveling Platinum Resistance Mechanisms in Ovarian Cancer Jingying Chen (Shandong University, China)

Åä·Ð 04¿ù 26ÀÏ 121/122 13:58~14:00 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 14:00~14:08 (ÃʷϹßÇ¥) Estrogen Receptor Downregulates Programmed Death Ligand-1 and Associated with Clinicopathological of type 1 Endometrial Carcinoma Setyo Teguh Waluyo(Lambung Mangkurat University, Indonesia)

Åä·Ð 04¿ù 26ÀÏ 121/122 14:08~14:10 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 14:10~14:18 (ÃʷϹßÇ¥) Stearate-rich diet and oleate restriction directly inhibit tumor growth via the unfolded protein response Jumpei Ogura(Kyoto University, Japan)

Åä·Ð 04¿ù 26ÀÏ 121/122 14:18~14:20 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 14:20~14:28 (ÃʷϹßÇ¥) Factors Influencing Single Agent Methotrexate Chemotherapy Resistance in Low Risks Gestational Trophoblastic Neoplasia in Indonesia Single Center Trophoblast Study Febia Erfiandi (Padjadjaran University, Indonesia)

Åä·Ð 04¿ù 26ÀÏ 121/122 14:28~14:30 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 14:30~14:38 (ÃʷϹßÇ¥) Survival in Patients with Recurrent or Progressive Uterine Carcinosarcoma Kanakarn Wangrangsimakul(Songkhlanagarind Hospital, Thailand)

Åä·Ð 04¿ù 26ÀÏ 121/122 14:38~14:40 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 14:40~14:48 (ÃʷϹßÇ¥) Trends and Outcomes of Minimally Invasive Surgery for Endometrial Cancer in Kanagawa Academic Institutions: A Retrospective Observational Study Jun Takeuchi (St. Marianna University, Japan)

Åä·Ð 04¿ù 26ÀÏ 121/122 14:48~14:50 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 15:20~15:30 On the radical hysterectomy Yusuke Kobayashi (Keio University, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 15:30~15:40 Pros ±è¼¼ÀÍ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 121/122 15:40~15:50 Cons ¹ÚÁ¤¿­(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 26ÀÏ 121/122 15:50~16:00 Floor discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:00~16:05 (ÃʷϹßÇ¥) Serial circulating-tumor DNA analysis with a tumor naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer ±èÀ¯³ª(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:05~16:10 (ÃʷϹßÇ¥) The efficacy of subsequent chemotherapy in ovarian cancer patients who progressed in prior PARPi ±èÁ¤Ã¶(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:10~16:15 (ÃʷϹßÇ¥) Anti-cancer effect of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer ÀÌÁ¤¿ø(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:15~16:20 (ÃʷϹßÇ¥) Application of Machine Learning Algorithms for Risk Stratification and Efficacy Evaluation in Cervical Cancer Screening among Low- Grade Abnormal Cytology Population: Evidence from the Korean HPV Cohort Study ¼ÛÈñ°æ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:20~16:25 (ÃʷϹßÇ¥) Development of a next-generation sequencing cancer panel‐based homologous recombination deficiency test in epithelial ovarian cancer ±è¼¼ÀÍ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:25~16:30 (ÃʷϹßÇ¥) ZBTB8A promotes ovarian cancer metastasis through interacting with ACOT12 Zhang Jinging(Shandong University, China)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:30~16:35 (ÃʷϹßÇ¥) Consideration of Fertility-Preserving Treatment for Cervical Cancer Based on the Evolution Masato Tamate(Sapporo Medical University, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:00~16:05 (ÃʷϹßÇ¥) Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment ÀåÀººñ(°Ç±¹ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:05~16:10 (ÃʷϹßÇ¥) Identification of Tumor-Specific Genes in Cervix sample of Ovarian Cancer Patients ÀåÁö¼±(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:10~16:15 (ÃʷϹßÇ¥) A phase 1/2a, dose-escalation, safety, and preliminary efficacy randomized trial of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2 Á¤¼ÒÇö(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:15~16:20 (ÃʷϹßÇ¥) Usefulness of magnetic resonance imaging before hysterectomy in detecting occult invasive cervical cancer in patients scheduled for hysterectomy due to high-grade and microinvasive cervical disease ÀÌÁö¹Î(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:20~16:25 (ÃʷϹßÇ¥) Multicenter Retrospective Analysis of Neuroendocrine Carcinoma of the Cervix: Clinical Behavior, Treatment Patterns, and Prognostic Outcomes. Takuya Kuboya(University of Tsukuba, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:25~16:30 (ÃʷϹßÇ¥) Combined oral contraceptives and endometrial cancer among Southeast Asian women: A secondary analysis of multicenter case-control study Kuntima Kantawee (Khon Kaen University, Thailand)

±³À°½Ã°£ 04¿ù 26ÀÏ 5AHall 16:30~16:35 (ÃʷϹßÇ¥) KNOWLEDGE OF HUMAN PAPILLOMAVIRUS VACCINE AND INFECTION IN SECONDARY SCHOOL STUDENTS FROM NORTHERN THAILAND: POST COVID-19 ERA. Napat Likkasittipan(Chiang Mai University, Thailand)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 16:40~17:40 Advancing Treatment for HPV-Independent Cervical Cancer and Enhancing CCRT Outcomes ±èÇö¼ö, ³²ÁöÈ£, ¹Ú¼ºÅÃ(¼º±Õ°üÀÇ´ë, ºÎ»êÀÇ´ë, ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 16:10~16:30 ºÎÀÎ¾Ï Ä¡·á¿¡¼­ÀÇ Ç¥Àû*¸é¿ª Ç×¾ÏÁ¦ Àû¿ë À¯¼±¿µ(¼­¿ï¾Æ»êº´¿ø °£È£»ç)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 16:30~16:50 Ç¥Àû*¸é¿ª Ç×¾ÏÁ¦ Àû¿ë¿¡ µû¸¥ ºÎÀÛ¿ë °ü¸® ±èÁÖÇö(»ï¼º¼­¿ïº´¿ø °£È£»ç)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 16:50~17:10 °¡ÀÓ·Â º¸Á¸À» Èñ¸ÁÇÏ´Â ÀþÀº ºÎÀÎ¾Ï È¯ÀÚ °ü¸® Á¶Çö¿õ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 26ÀÏ 321/322/323/324 17:10~17:30 ºÎÀÎ¾Ï »ýÁ¸ÀÚÀÇ ÀçÈ°°ú ¿îµ¿ ±èÈï¼ö(´ëÇѾÏÀçÈ°¿¬±¸¼Ò ¿¬±¸¿ø)

Åä·Ð 04¿ù 26ÀÏ 17:30~17:40 Discussion ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-04-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѳ»°úÇÐȸ (¿Â¶óÀÎ) 2024³â Á¦18ȸ ³»°úÀü°øÀÇ Çٽɿª·® ¿¬¼ö°­Á : 2024-04-26
´ÙÀ½±Û (¿Â¶óÀÎ) 2024³â Á¦1Â÷ ´ëÇÑÇÙÀÇÇÐȸ Çмú±âȹ ¿Â¶óÀÎ ±³À° : 2024-04-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 0 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 1 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 0 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 1 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 0 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 1 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 0 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 2 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 1 2024-04-29
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 0 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 2 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 5 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 1 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 0 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 0 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷